Canine Disseminated Mast Cell Tumor Study Guide

Overview and Clinical Importance

Disseminated mast cell tumor (MCT) represents the most severe presentation of mast cell neoplasia in dogs, characterized by widespread systemic involvement beyond the primary cutaneous site. While solitary cutaneous MCTs are the most common skin tumor in dogs (accounting for 16-21% of all cutaneous neoplasms), the disseminated form carries a significantly worse prognosis. Understanding the pathophysiology, staging, and management of disseminated MCT is essential for NAVLE success, as these cases require rapid recognition and aggressive multimodal therapy.

Disseminated MCT involves spread to multiple organ systems including regional lymph nodes, liver, spleen, bone marrow, and occasionally the lungs. The condition may also manifest as systemic mastocytosis (mast cells infiltrating bone marrow), mastocytemia (circulating mast cells in peripheral blood), or mast cell leukemia (uncontrolled proliferation in bone marrow). These conditions represent a continuum of disease severity with profound clinical implications.

Etiology and Breed Predisposition

The exact etiology of MCT remains incompletely understood, but c-KIT proto-oncogene mutations play a central role in tumor development and progression. The c-KIT gene encodes a receptor tyrosine kinase (KIT) that binds stem cell factor (SCF) and regulates mast cell growth, differentiation, and survival. Internal tandem duplications (ITD) in exon 11 of c-KIT occur in 20-30% of cutaneous MCTs and are strongly associated with aggressive behavior and disseminated disease.